Hanover - Delayed Quote ? EUR Coloplast A/S (CBHD.HA) Follow Compare 118.05 -1.85 (-1.54%) At close: October 25 at 5:25 PM GMT+2 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Coloplast A/S - FY 2023/24 Earnings Release - Invitation for conference call on 5 November 2024 at 11.00 CET Tuesday, 5 November 2024 at 11.00 – 12.00 CETIn connection with the publication of Coloplast's interim financial results for FY 2023/24 the company will host a conference call to present the financial results and answer questions from investors and financial analysts.A presentation will be available on Coloplast's website approximately 1 hour before the conference call.Please note that the webcast of the conference call will be available during and after the event. Coloplast will be represented GlobeNewswire ? 6 days ago CLPBF CLPBY Coloplast A/S - Financial Calendar 2024-25 Please see enclosed pdf. For more information and calendar invitations for upcoming events, please visit: https://investor.coloplast.com/investor-relations/financial-calendar-and-events/ Kind regards,Investor RelationsColoplast A/STel. +45 4911 1800 For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. +45 4911 1111 Aleksandra DimovskaVice President, Investor RelationsTel. +45 4911 1800 / +45 4911 2458Email: [email protected] K GlobeNewswire ? last month CLPBF CLPBY Recent Price Trend in Coloplast A/S Sponsored ADR (CLPBY) is Your Friend, Here's Why If you are looking for stocks that are well positioned to maintain their recent uptrend, Coloplast A/S Sponsored ADR (CLPBY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. Zacks ? 2 months ago COLO-B.CO Coloplast A/S - Interim Financial Report, 9M 2023/24 9M 2023/24Interim financial results, 9M 2023/241 October 2023 - 30 June 2024 Coloplast delivered 8% organic growth and an EBIT margin1) of 27% in Q3, with 11% growth in absolute EBIT1). Reported revenue in DKK grew 13% which includes 4%-points contribution from Kerecis (underlying growth of around 35%). Organic growth rates by business area: Ostomy Care 8%, Continence Care 8%, Voice and Respiratory Care 11%, Advanced Wound Care 13% (Advanced Wound Dressings 13%) and Interventional Urology 2%.Gro GlobeNewswire ? 2 months ago CLPBF CLPBY Stocks to watch this week: Palo Alto, Antofagasta, Analog Devices and Urban Outfitters Earnings preview of key companies reporting this week and what to look out for. Yahoo Finance UK ? 2 months ago CLPBF CLPBY AAGIY Coloplast A/S's Dividend Analysis Coloplast A/S (CLPBY) recently announced a dividend of $0.07 per share, payable on 2024-05-28, with the ex-dividend date set for 2024-05-17. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into Coloplast A/S's dividend performance and assess its sustainability. GuruFocus.com ? 5 months ago COLO-B.CO Coloplast A/S - Invitation to Coloplast's Meet the Management event on 6 June 2024 (gentle reminder) The event will take place on Thursday, 6 June 2024 at Coloplast’s HeadquartersHoltedam 3, 3050 Humlebaek, Denmarkfrom 11.30 - 18.00 CEST (Central European Summer Time) Coloplast invites institutional investors, equity analysts and media to attend our 2024 Meet the Management event.The event will be held in person at our headquarters in Humlebaek, Denmark, with the option to join us virtually for the plenary session.The purpose of the event is to provide participants with the opportunity to meet GlobeNewswire ? 5 months ago CLPBF CLPBY Coloplast expands its Luja? portfolio with next generation catheter for women Luja Female Luja Female is an intermittent catheter that enables complete bladder emptying in one free flow, aiming to reduce the risk of urinary tract infections. The female intermittent catheter enables complete bladder emptying in one free flow1, aiming to reduce the risk of urinary tract infections2. Following the successful launch of Luja with Micro-hole Zone Technology, a next generation intermittent catheter for men, Coloplast is now launching Luja for women. “So far, we have received gre GlobeNewswire ? 5 months ago CLPBF CLPBY Coloplast strengthens ostomy care portfolio with three significant product launches Heylo Heylo is the world's first digital leakage notification system. SenSuraMio_Black SenSura Mio in black developed to provide more product choice for people living with a stoma. The company has received reimbursement approval in the UK for Heylo?, the world’s first digital leakage notification system, and expands its SenSura? Mio ostomy range with two new products. As part of our 2025 strategy, Strive25, we set an ambition to significantly raise the standard of care for our users and bring ne GlobeNewswire ? 5 months ago CLPBF CLPBY Coloplast A/S - Announcement no. 02/2024 - Interim Financial Report, H1 2023/24 H1 2023/24Interim financial results, H1 2023/241 October 2023 - 31 March 2024 Coloplast delivered a solid Q2 with 8% organic growth and an EBIT margin1) of 27%. Reported revenue in DKK grew 9% with 4%-points contribution from Kerecis (underlying growth of around 35%), partly offset by currencies. Organic growth rates by business area: Ostomy Care 7%, Continence Care 8%, Voice and Respiratory Care 13%, Advanced Wound Care 8% (Advanced Wound Dressings 8%) and Interventional Urology 5%.Continued go GlobeNewswire ? 5 months ago CLPBF CLPBY Coloplast A/S - Allocation of Share Options Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities. The below transactions concern allocation of share options. For further details, reference is made to Coloplast’s Remuneration Policy. The policy is available on the group website at this address: https://investor GlobeNewswire ? 8 months ago CLPBF CLPBY Coloplast launches Peristeen? Light for people with bowel disorders Peristeen Light Peristeen Light is designed to bring relief. It is a hand-held, low-volume transanal irrigation device that instills water into the rectum, thereby evacuating the stool from the lower bowel. The new transanal irrigation device is designed to help people facing defecation issues or stool leakage. It is estimated that 10-15% of the world’s population are affected by chronic constipation1 and that 6% struggle with faecal incontinence2, both of which can cause physical discomfort and GlobeNewswire ? 8 months ago CLPBF CLPBY Coloplast A/S - Interim Financial Report, Q1 2023/24 Q1 2023/24Interim financial results, Q1 2023/241 October 2023 - 31 December 2023 Coloplast delivered a solid Q1 with 8% organic growth and an EBIT margin1) of 28%. Reported revenue in DKK grew 8% with 4%-points contribution from Kerecis (underlying growth of around 35%), offset by negative impact from currencies. Organic growth rates by business area: Ostomy Care 8%, Continence Care 8%, Voice and Respiratory Care 7%, Advanced Wound Care 9% (Advanced Wound Dressings 9%) and Interventional Urology GlobeNewswire ? 8 months ago CLPBF CLPBY Coloplast launches Biatain? Silicone Fit for pressure injury prevention and wound management in the US Biatain Silicone Fit Coloplast's Biatain Silicone Fit is developed for pressure injury prevention and wound management. The company aims to expand its position within advanced wound care by introducing a new silicone foam that will benefit both healthcare professionals and patients. “We are now introducing new innovation to the US market, aiming to grow our presence within the foam dressings segment. We have a great product in our hands, and we have invested significantly in our sales organizati GlobeNewswire ? 8 months ago CLPBF CLPBY Coloplast A/S - Q1 2023/24 Earnings Release - Invitation for conference call on 9 February 2024 at 11.00am CET Friday, 9 February 2024 at 11.00 - 12.00 CETIn connection with the publication of Coloplast’s interim financial results for Q1 2023/24, to be released same day around 07.30 am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.The webcast of the conference call will be available during and after the event. Col GlobeNewswire ? 9 months ago CLPBF CLPBY Coloplast A/S - Change of auditor Today, 7 December 2023, Coloplast A/S held its Annual General Meeting, at which EY Godkendt Revisionspartnerselskab was elected as Coloplast A/S’ auditors in line with the proposal from the Board of Directors. For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. +45 4911 1111 Aleksandra DimovskaSenior Director, Investor RelationsTel. +45 4911 1800 / +45 4911 2458Email: [email protected] Kristine Husted MunkSenior Manager, Inve GlobeNewswire ? 10 months ago CLPBF CLPBY Coloplast A/S - Articles of Association Articles of association for Coloplast A/S as adopted at the Annual General Meeting of Coloplast A/S held today, 7 December 2023 are enclosed. For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. +45 4911 1111 Aleksandra DimovskaSenior Director, Investor RelationsTel. +45 4911 1800 / +45 4911 2458Email: [email protected] Kristine Husted MunkSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 3266Email: dkkhu@colopla GlobeNewswire ? 10 months ago CLPBF CLPBY Coloplast A/S - Decisions at the Annual General Meeting 2023 Today, 7 December 2023, Cololast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2022/23 was approved.Distribution of year-end dividend of DKK 16 per share of nominally DKK 1 was approved. In addition to the interim dividend of DKK 5.00 per share of nominally DKK 1 paid out in connection with Coloplast A/S’ half-year result, this brings the total dividend paid for the financial year 2022/23 to DKK 21.00 per share of n GlobeNewswire ? 10 months ago CLPBF CLPBY Coloplast A/S - Notice of Annual General Meeting 2023 The Annual General Meeting of Coloplast A/S will be held on Thursday, 7 December 2023 at 3:30 pm CET at the premises of Coloplast A/S, Holtedam 3 in Humleb?k (the Aage Louis-Hansen Auditorium), Humleb?k, Denmark. The notice of the Annual General Meeting is enclosed. For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. +45 4911 1111 Aleksandra DimovskaSenior Director, Investor RelationsTel. +45 4911 1800 / +45 4911 2458Email: dkad GlobeNewswire ? 11 months ago CLPBF CLPBY Coloplast announces new manufacturing site in Portugal Coloplast, a leading company within intimate healthcare, will invest around 100 million euros in a new manufacturing site in Portugal to support the company’s continued growth. The new manufacturing site will produce Coloplast’s intermittent catheters used by people suffering from urinary retention, such as people with spinal cord injury or spina bifida, who are unable to empty their bladder. With the new site, Coloplast aims to meet the increasing global demand for intermittent catheters, with GlobeNewswire ? 11 months ago CLPBF CLPBY Performance Overview Trailing total returns as of 10/25/2024, which may include dividends or other distributions. Benchmark is OMX Copenhagen 25 Index Return CBHD.HA OMX Copenhagen 25 Index YTD +18.68% +5.36% 1-Year +50.84% +19.08% 3-Year +41.68% -2.42%
